Semax vs Selank: Comparing Two Nootropic Peptides
Semax and Selank get mentioned together so often that people assume they are interchangeable. They are not. Both came out of the Russian Academy of Sciences, both are heptapeptides, and both have decades of clinical use behind them in Russia. But they were built to solve different problems, they work through different mechanisms, and they feel different to the people who use them.
This article breaks down what separates the two, where they overlap, and why a lot of researchers end up running them together rather than picking one.
The Short Version
If you only read one paragraph: Selank is the calm one and Semax is the sharp one. Selank is primarily an anxiolytic that happens to have nootropic side benefits. Semax is primarily a nootropic and neuroprotectant that happens to have mood-stabilizing side benefits. Selank works on the GABA system without sedating you. Semax works on BDNF and dopamine without acting like a stimulant. Neither builds physical dependence, and the two are commonly stacked because they cover each other’s gaps.
The rest of this article is the long version.
Side-by-Side Overview
| Attribute | Selank | Semax |
|---|---|---|
| Primary effect | Anxiolytic, secondary nootropic | Nootropic and neuroprotectant, secondary mood support |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) | Met-Glu-His-Phe-Pro-Gly-Pro |
| Derived from | Tuftsin (immunoglobulin G fragment) | ACTH(4-10) |
| Core mechanism | Positive allosteric modulation of GABAa | BDNF and TrkB upregulation, dopamine and serotonin modulation |
| Onset | Gradual, builds over 1 to 3 days | Fast, often noticeable within the first few doses |
| Stimulating | No | Moderate |
| Anxiolytic | Strong | Mild |
| Dependence or withdrawal | None reported | None reported |
| Russian clinical use | Anxiety disorders, neurasthenia | Stroke, TBI, cognitive decline, optic nerve disorders |
| US status | Research compound, not FDA approved, not scheduled | Research compound, not FDA approved, not scheduled |
Where They Came From
Both peptides are products of the same research lineage, which is part of why they pair so naturally.
Selank is a synthetic analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) found in the heavy chain of human immunoglobulin G. Researchers added a Pro-Gly-Pro tripeptide to the C-terminus, which made the molecule metabolically stable enough to cross the blood-brain barrier and act on the central nervous system. It was developed specifically as an alternative to benzodiazepines and has been a prescription anxiolytic in Russia since the early 2000s.
Semax is a synthetic fragment of adrenocorticotropic hormone, based on the ACTH(4-10) sequence that carries the cognitive effects of the hormone, modified for stability and brain penetration. The name comes from the Russian for “seven amino acids.” It has been used clinically in Russia for decades and sits on Russia’s List of Vital and Essential Drugs.
The shared origin matters less than the shared design philosophy. Both were engineered to deliver a clinical effect through endogenous regulatory pathways rather than brute-force receptor activation. That is why neither one produces the crash, the dependence, or the cognitive dulling you see with the conventional drugs they were designed to replace.
How They Work
This is where the two peptides genuinely diverge.
Selank: GABA Without the Sedation
Selank’s headline mechanism is positive allosteric modulation of the GABAa receptor. GABA is the brain’s main inhibitory neurotransmitter. Benzodiazepines, barbiturates, and alcohol all hit this same system, but they do it by directly activating the receptor, which is what produces sedation, amnesia, tolerance, and dependence.
Selank does something more subtle. Instead of binding the primary site, it appears to bind a related but distinct allosteric site, shifting the receptor’s conformation so that GABA itself binds more effectively. You get enhanced inhibitory signaling without the receptor being forced open. Radioligand work (Kasian et al., 2019) showed Selank can compete with diazepam for binding on the receptor complex while producing functionally different downstream effects, which is the biochemical fingerprint of an allosteric modulator rather than a direct agonist.
That is not its only pathway. Selank also:
- Upregulates BDNF in the hippocampus and prefrontal cortex, which is the basis for its cognitive benefit (Inozemtseva et al., 2008)
- Modulates serotonin and dopamine, contributing to mood stability and the “calm focus” users describe
- Inhibits enkephalin degradation. GAD patients show depressed enkephalin levels, and Selank treatment raised them while improving symptoms (Zozulia et al., 2008)
- Retains immunomodulatory activity from tuftsin, including effects on cytokines and antiviral activity in influenza models (Ershov et al., 2009)
Semax: Building Capacity Through BDNF
Semax is essentially a BDNF lever. Brain-derived neurotrophic factor supports neuron survival, drives the growth of new neurons, and strengthens synaptic connections. More BDNF correlates with better learning and memory consolidation.
A single dose of Semax has been shown to raise BDNF protein by roughly 1.4-fold and BDNF mRNA by up to 3-fold, while increasing TrkB receptor phosphorylation 1.6-fold (Dolotov et al., 2006). TrkB is the receptor BDNF signals through, so Semax is not just producing more of the growth factor, it is amplifying the brain’s ability to respond to it.
On top of the neurotrophic action, Semax:
- Modulates neurotransmitters, raising serotonin metabolites about 25 percent in the striatum and potentiating dopamine release, especially alongside stimulants (Eremin et al., 2005)
- Triggers a broad gene-expression response. In a stroke model it affected 96 genes at three hours post-dose, more than half related to immune and vascular function (Medvedeva et al., 2014)
- Interacts with melanocortin receptors, acting as a competitive antagonist at MC4 and MC5
- Provides neuroprotection under oxidative stress and hypoxia, and inhibits enkephalin-degrading enzymes
The contrast is clean. Selank quiets an overactive stress system. Semax builds the underlying hardware. One is regulatory, the other is constructive.
What the Evidence Actually Shows
Both peptides have more human data behind them than most research compounds, which is worth saying plainly. The bulk of it comes from Russian clinical literature. That is not a reason to dismiss it, but it is a reason to read it with the same scrutiny you would apply to any single-country research base: the findings are consistent across multiple groups and models, and the absence of a Western regulatory file reflects which markets pursued approval, not a verdict on the data.
Selank’s Strongest Studies
- Zozulia et al. (2008): Compared Selank to medazepam in 62 GAD and neurasthenia patients. Comparable anxiety reduction on the Hamilton and Zung scales, but Selank also produced anti-asthenic and mild psychostimulant effects the benzodiazepine did not. First evidence tying its mechanism to enkephalin modulation.
- Seredenin et al. (2014): Selank versus phenazepam in 60 anxiety patients. Pronounced anxiolytic effect with mild nootropic benefit, and notably the effect persisted for a week after the last dose. That persistence argues for a restorative rather than purely suppressive action.
- Filatova et al. (2017) and Volkova et al. (2016): Gene-expression work showing Selank alters dozens of GABAergic neurotransmission genes within an hour, correlated with but not identical to GABA’s own profile, which is consistent with allosteric rather than direct action.
Semax’s Strongest Studies
- Dolotov et al. (2006): The foundational BDNF study described above, establishing the BDNF and TrkB mechanism.
- Gusev et al. (2018): 110 stroke patients on a 6,000 mcg/day protocol. Semax raised BDNF plasma levels regardless of rehabilitation timing, and higher BDNF correlated with better functional independence and motor recovery.
- Eremin et al. (2005): Documented the dopaminergic and serotonergic activation underlying the mood and focus effects.
- Optic nerve studies: Patients with glaucomatous optic neuropathy showed visual field expansion averaging 57.5 degrees in 80 percent of treated eyes after 30 days.
The pattern is telling. Selank’s best evidence is in anxiety. Semax’s best evidence is in cognition and neurological recovery. The research tracks the intended use of each peptide.
Stacking Them Together
This is the part most people are actually building toward. Selank and Semax are one of the most established peptide stacks in both research and clinical settings, precisely because their profiles are complementary rather than redundant.
Semax sharpens focus and drive. Selank takes the edge off without dulling anything. Run together, the reported result is calm focus: the productive alertness of Semax with the anxiety floor of Selank, minus the jitter or the sedation you would get trying to engineer the same state with stimulants and benzodiazepines.
A common morning protocol:
- Semax: 300 to 400 mcg
- Selank: 200 to 300 mcg
They work through entirely different mechanisms (BDNF and dopamine versus GABA modulation), which is why they are generally described as having no meaningful interaction concerns. As with any stack, the conservative approach is to introduce one at a time so you know which compound is producing which effect before combining them.
Side Effects and Safety
Both have favorable tolerability profiles in the available data, but they are not identical.
| Selank | Semax | |
|---|---|---|
| Most common issue | Mild nasal irritation (intranasal) | Nasal irritation, temporary yellowish nasal discoloration |
| Other reported effects | Transient headache, occasional mild fatigue | Headache, dizziness, sleep disruption if dosed late |
| Notable population effect | None specific | Glucose elevation in diabetics (about 7.4% in clinical data) |
| Does not cause | Sedation, cognitive impairment, dependence | Dependence, appetite suppression, cardiovascular effects. |
The one Semax-specific flag worth highlighting is glucose. Diabetic users should monitor blood glucose closely. Semax also carries cautions around active cancer (BDNF can theoretically support tumor growth), seizure history, and bipolar disorder, all of which trace back to its neurotrophic and mood-pathway activity. Selank’s main cautions involve combining with other GABAergic compounds, serotonergic medications, and autoimmune conditions given its immunomodulatory action.
Neither has been studied in pregnancy or breastfeeding, so both should be avoided in those populations. And neither is a substitute for proper sleep, nutrition, stress management, or professional evaluation of an underlying condition.
Which One Should You Use?
The honest answer is that the question is usually framed wrong. People ask “Semax or Selank” as if they are competing for the same slot. They are not.
- If your primary issue is anxiety, stress reactivity, or feeling wired and overstimulated, Selank is the more targeted choice. It addresses the stress response at the GABA and HPA-axis level without flattening you.
- If your primary goal is focus, learning, memory, or recovering cognitive sharpness, Semax is the more targeted choice. It is the better learning and performance tool.
- If you want both, which is most people, the stack is the well-trodden path rather than a compromise.
Selank is the calm. Semax is the sharp. The reason they are mentioned in the same breath so often is not that they are alternatives, it is that together they cover the full range of “I want to think clearly and not feel stressed while I do it.”
To learn more about these compounds and other peptides join the free Skool group here.
Frequently Asked Questions
Is one stronger than the other? They are not on the same scale. Selank is the stronger anxiolytic, Semax is the stronger nootropic. Comparing their raw “strength” is like comparing a stronger painkiller to a stronger stimulant.
Which works faster? Semax. Effects are often noticeable within the first few doses, and animal studies show cognitive changes within 15 minutes. Selank is more gradual, building over one to three days.
Can I run them at the same time? That is the standard stack. Different mechanisms, complementary effects, no documented interaction concerns. Morning dosing for both is typical.
Do either of them build dependence? No physical dependence or withdrawal has been reported for either. Semax does build tolerance to its cognitive effect with continuous use, which is why cycling matters, but that is downregulation, not dependence.
Nasal spray or injection? Both routes work for both peptides. Intranasal is the traditional Russian clinical route and gives fast absorption with some direct CNS delivery. Subcutaneous gives more consistent, predictable dosing. It comes down to preference.